Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free MIRA Stock Alerts

MIRA Pharmaceuticals (MIRA) Competitors

MIRA Pharmaceuticals logo
$0.78 +0.03 (+4.01%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 +0.01 (+1.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MIRA vs. CPIX, PLYX, NRXP, RFL, and ICCC

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MIRA Pharmaceuticals's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), NRx Pharmaceuticals (NRXP), Rafael (RFL), and ImmuCell (ICCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MIRA Pharmaceuticals compare to Cumberland Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MIRA PharmaceuticalsN/A -106.95% -104.18%
Cumberland Pharmaceuticals -34.40%-28.81%-9.25%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cumberland Pharmaceuticals has higher revenue and earnings than MIRA Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A
Cumberland Pharmaceuticals$44.52M2.62-$2.84M-$0.71N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat Cumberland Pharmaceuticals' score of 0.85 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
MIRA Pharmaceuticals Positive
Cumberland Pharmaceuticals Positive

MIRA Pharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Summary

MIRA Pharmaceuticals and Cumberland Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Polaryx Therapeutics had 4 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 6 mentions for Polaryx Therapeutics and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat Polaryx Therapeutics' score of 1.21 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Polaryx Therapeutics Positive
MIRA Pharmaceuticals Positive

Polaryx Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than MIRA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
MIRA Pharmaceuticals N/A -106.95%-104.18%

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.05N/A
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A

Summary

Polaryx Therapeutics beats MIRA Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

NRx Pharmaceuticals presently has a consensus price target of $34.50, indicating a potential upside of 955.05%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

NRx Pharmaceuticals' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
MIRA Pharmaceuticals N/A -106.95%-104.18%

MIRA Pharmaceuticals has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M96.32-$28.62M-$1.09N/A
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat NRx Pharmaceuticals' score of 0.04 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
NRx Pharmaceuticals Neutral
MIRA Pharmaceuticals Positive

Summary

NRx Pharmaceuticals beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Rafael?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for Rafael. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat Rafael's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
MIRA Pharmaceuticals Positive
Rafael Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rafael
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

MIRA Pharmaceuticals has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A
Rafael$920K113.44-$30.52M-$0.68N/A

MIRA Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MIRA PharmaceuticalsN/A -106.95% -104.18%
Rafael -3,321.74%-41.27%-35.32%

MIRA Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MIRA Pharmaceuticals beats Rafael on 9 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to ImmuCell?

MIRA Pharmaceuticals (NASDAQ:MIRA) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

ImmuCell has higher revenue and earnings than MIRA Pharmaceuticals. ImmuCell is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A
ImmuCell$27.64M3.29-$1.04M-$0.06N/A

ImmuCell has a net margin of 2.57% compared to MIRA Pharmaceuticals' net margin of 0.00%. ImmuCell's return on equity of 2.75% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MIRA PharmaceuticalsN/A -106.95% -104.18%
ImmuCell 2.57%2.75%1.79%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ImmuCell
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ImmuCell had 6 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for ImmuCell and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat ImmuCell's score of 0.58 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
MIRA Pharmaceuticals Positive
ImmuCell Positive

MIRA Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

ImmuCell beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MIRA vs. The Competition

Export
MetricMIRA PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$31.52M$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio-0.60775.15269.0625.28
Price / SalesN/A743.86602.4391.76
Price / CashN/A66.4570.4850.90
Price / Book4.1111.6012.916.24
Net Income-$10.44M$2.77B$3.45B$347.60M
7 Day Performance5.43%0.17%1.12%1.07%
1 Month Performance-14.27%0.35%1.79%1.03%
1 Year Performance-46.93%161.52%67.69%20.77%

MIRA Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MIRA
MIRA Pharmaceuticals
1.3727 of 5 stars		$0.78
+4.0%		N/A-49.7%$31.52MN/AN/A2
CPIX
Cumberland Pharmaceuticals
0.6213 of 5 stars		$7.59
+5.7%		N/A+169.6%$113.72M$41.94MN/A80
PLYX
Polaryx Therapeutics
4.4887 of 5 stars		$2.24
+2.5%		$8.50
+278.8%		N/A$111.85MN/AN/A11
NRXP
NRx Pharmaceuticals
2.3084 of 5 stars		$3.06
-5.4%		$38.25
+1,148.4%		+32.0%$111.01M$1.23MN/A2
RFL
Rafael
0.1718 of 5 stars		$1.96
-2.3%		N/A+21.6%$101.40M$920KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel